Skip to content

A SMART Design for Attendance-based Prize CM

A SMART Design for Attendance-based Prize CM

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00840151
Enrollment
360
Registered
2009-02-10
Start date
2009-01-31
Completion date
2014-08-31
Last updated
2019-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Abuse

Keywords

Substance Abuse, Contingency Management

Brief summary

The purpose of this study is to compare different forms of treatment for substance abuse. This study will involve a type of treatment called contingency management, in which patients receive incentives (prizes) for attending outpatient treatment. This study will compare contingency management to standard treatment that does not involve incentives. This study will also compare contingency management treatment that lasts 6 weeks to contingency management that lasts 12 weeks. Finally, this study will compare contingency management treatment delivered at the beginning of outpatient treatment to contingency management treatment delivered later during outpatient treatment. The investigators hypothesize that (1) a 12-week attendance-based contingency management intervention will improve retention and enhance drug abstinence versus standard treatment, (2) initial short-term exposure to attendance-based contingency management (in weeks 1-6 only) will improve substance abuse treatment outcomes compared to standard treatment alone, and (3) contingency management in weeks 7-12 will be particularly useful for those with sporadic attendance or continued drug use during initial stages of treatment.

Interventions

BEHAVIORALcontingency management

Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
UConn Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * current DSM-IV diagnosis of cocaine abuse or dependence or recent cocaine use (self-reported use in past 30 days or positive urine toxicology screen) * willing to sign informed consent and able to pass an informed consent quiz

Exclusion criteria

* serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination * in recovery from pathological gambling (meet DSM-IV criteria for lifetime pathological gambling and are actively trying to refrain from gambling) * do not speak English (all treatment is provided in English at these clinics)

Design outcomes

Primary

MeasureTime frame
longest duration of negative drug and alcohol samples submittedthroughout active phase and at each follow-up assessment

Secondary

MeasureTime frame
proportions of samples testing negative for drugs and alcoholduring active phase and at each follow-up assessment
psychosocial functioning and HIV risk behaviorsbaseline, active phase and at each follow-up assessment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026